To assess the efficacy and tolerability of pravastatin in the chronic treatment of subjects with mild hypercholesterolemia and associated coronary heart disease (CHD) risk factors, 32 outpatients (16 normotensives and 16 well-controlled hypertensives), with plasma total cholesterol (TC) levels between 200 and 260 mg/dl and at least two concomitant CHD risk factors, were randomly treated with pravastatin 20 mg daily or placebo for 26 weeks. All subjects were maintained on a lipid-lowering diet throughout the study. Pravastatin, but not placebo, significantly reduced TC by 16% to 20%, low-density lipoprotein cholesterol by 20% to 21%, and triglycerides by -16% to -19%. Such changes were already significant after six weeks of treatment and persisted after 26 weeks. In treated hypertensive patients pravastatin produced a similar reduction in the plasma lipid fractions without affecting the efficacy of antihypertensive therapy. No serious laboratory, clinical, or ocular abnormalities were observed. These data suggest that pravastatin is an effective and generally well-tolerated treatment for patients with mild hypercholesterolemia and concomitant CHD risk factors.
|Number of pages||10|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1992|
ASJC Scopus subject areas